{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:51:04Z","timestamp":1793224264309,"version":"4.5.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41591-025-03813-5","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:03:10Z","timestamp":1752656590000},"page":"2132-2146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Noncanonical and mortality-defining toxicities of CAR T cell therapy"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"3813_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"3813_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"3813_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212\u20132221 (2019).","journal-title":"Blood"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142, 1243\u20131248 (2023).","journal-title":"Blood"},{"key":"3813_CR10","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn, K. et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 4, 3024\u20133033 (2020).","journal-title":"Blood Adv."},{"key":"3813_CR11","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain, T. et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 4, 3776\u20133787 (2020).","journal-title":"Blood Adv."},{"key":"3813_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J. Hematol. Oncol. 16, 88 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138, 2499\u20132513 (2021).","journal-title":"Blood"},{"key":"3813_CR14","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere 7, e889 (2023).","journal-title":"Hemasphere"},{"key":"3813_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142, 865\u2013877 (2023).","journal-title":"Blood"},{"key":"3813_CR16","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski, K., Jain, M. D., Shah, N. N., Perales, M. A. & Subklewe, M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 11, e459\u2013e470 (2024).","journal-title":"Lancet Haematol."},{"key":"3813_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill, J. A. et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131, 121\u2013130 (2018).","journal-title":"Blood"},{"key":"3813_CR18","doi-asserted-by":"publisher","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J. Immunother. Cancer 10, e004475 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3813_CR19","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","volume":"8","author":"C Gudiol","year":"2021","unstructured":"Gudiol, C., Lewis, R. E., Strati, P. & Kontoyiannis, D. P. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 8, e216\u2013e228 (2021).","journal-title":"Lancet Haematol."},{"key":"3813_CR20","doi-asserted-by":"crossref","unstructured":"Kampouri, E. et al. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl. Infect. Dis. e14157 (2023).","DOI":"10.1111\/tid.14157"},{"key":"3813_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn, K. et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 10, 79 (2020).","journal-title":"Blood Cancer J."},{"key":"3813_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill, J. A. & Seo, S. K. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136, 925\u2013935 (2020).","journal-title":"Blood"},{"key":"3813_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.2024023933","volume":"144","author":"C Diorio","year":"2024","unstructured":"Diorio, C. et al. Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents. Blood 144, 1387\u20131398 (2024).","journal-title":"Blood"},{"key":"3813_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl. Cell Ther. 29, 431\u2013438 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"3813_CR25","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain, M. D., Smith, M. & Shah, N. N. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141, 2430\u20132442 (2023).","journal-title":"Blood"},{"key":"3813_CR26","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"3813_CR27","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain, M. D. et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 42, 3581\u20133592 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3813_CR28","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","volume":"7","author":"J Lemoine","year":"2023","unstructured":"Lemoine, J. et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 7, 6589\u20136598 (2023).","journal-title":"Blood Adv."},{"key":"3813_CR29","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr.","year":"2008","unstructured":"DeVita, V. T. Jr. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"3813_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR31","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"3813_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/bloodadvances.2023012336","volume":"8","author":"R Banerjee","year":"2024","unstructured":"Banerjee, R. et al. Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic. Blood Adv. 8, 895\u2013898 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"3813_CR35","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix, T. et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin. Cancer Res. 30, 4690\u20134700 (2024).","journal-title":"Clin. Cancer Res."},{"key":"3813_CR36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"3813_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamaoncol.2024.0662","volume":"10","author":"R Storgard","year":"2024","unstructured":"Storgard, R., Rejeski, K., Perales, M. A., Goldman, A. & Shouval, R. T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 10, 826\u2013828 (2024).","journal-title":"JAMA Oncol."},{"key":"3813_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"3813_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro, A. et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 26, 26\u201333 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"3813_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1063986","volume":"13","author":"A Zhao","year":"2022","unstructured":"Zhao, A. et al. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: case series and review of literature. Front. Immunol. 13, 1063986 (2022).","journal-title":"Front. Immunol."},{"key":"3813_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"3813_CR42","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"3813_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","volume":"6","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl, A. et al. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 6, 321\u2013326 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","volume":"30","author":"W Wesson","year":"2024","unstructured":"Wesson, W. et al. Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma. Transpl. Cell Ther. 30, 876\u2013884 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"3813_CR45","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","volume":"8","author":"N Ahmed","year":"2024","unstructured":"Ahmed, N. et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 8, 5346\u20135354 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin, M. et al. Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol. 10, 115\u2013121 (2024).","journal-title":"JAMA Oncol."},{"key":"3813_CR47","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"3813_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"3813_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"3813_CR50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142 (2020).","journal-title":"Cell"},{"key":"3813_CR51","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein, D. A. et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood 138, 2469\u20132484 (2021).","journal-title":"Blood"},{"key":"3813_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank, M. J. et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404, 353\u2013363 (2024).","journal-title":"Lancet"},{"key":"3813_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana, S. et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood 145, 85\u201397 (2025).","journal-title":"Blood"},{"key":"3813_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen, A. D. et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 12, 32 (2022).","journal-title":"Blood Cancer J."},{"key":"3813_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR56","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar, A. D. et al. Delayed neurotoxicity after CAR-T in multiple myeloma: results from a Global IMWG Registry. Blood 144, 4758\u20134758 (2024).","journal-title":"Blood"},{"key":"3813_CR57","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2023-178743","volume":"142","author":"NWCJ Van De Donk","year":"2023","unstructured":"Van De Donk, N. W. C. J. et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (Cilta-cel). Blood 142, 3501\u20133501 (2023).","journal-title":"Blood"},{"key":"3813_CR58","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3324\/haematol.2023.283296","volume":"109","author":"YK Kathari","year":"2024","unstructured":"Kathari, Y. K. et al. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica 109, 682\u2013688 (2024).","journal-title":"Haematologica"},{"key":"3813_CR59","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham, C. E. et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 142, 1248\u20131252 (2023).","journal-title":"Blood"},{"key":"3813_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna, G. G. et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 14, 180 (2024).","journal-title":"Blood Cancer J."},{"key":"3813_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.it.2017.10.006","volume":"39","author":"FL Jahnsen","year":"2018","unstructured":"Jahnsen, F. L., B\u00e6kkevold, E. S., Hov, J. R. & Landsverk, O. J. Do long-lived plasma cells maintain a healthy microbiota in the gut? Trends Immunol. 39, 196\u2013208 (2018).","journal-title":"Trends Immunol."},{"key":"3813_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz, M. et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. Hemasphere 9, e70070 (2025).","journal-title":"Hemasphere"},{"key":"3813_CR63","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen, D. K. et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 1597\u20131609 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3813_CR64","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-Targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR65","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","volume":"21","author":"P Neri","year":"2024","unstructured":"Neri, P. et al. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat. Rev. Clin. Oncol. 21, 590\u2013609 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3813_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero, P. et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 14, 24 (2024).","journal-title":"Blood Cancer J."},{"key":"3813_CR67","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"S Bal","year":"2024","unstructured":"Bal, S. et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G-protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed\/refractory (RR) multiple myeloma (MM). Blood 144, 922 (2024).","journal-title":"Blood"},{"key":"3813_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.72","volume":"8","author":"A Perthus","year":"2024","unstructured":"Perthus, A. et al. Remission after CAR T-cell therapy: do lymphoma patients recover a normal life? Hemasphere 8, e72 (2024).","journal-title":"Hemasphere"},{"key":"3813_CR69","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","volume":"7","author":"PC Johnson","year":"2023","unstructured":"Johnson, P. C. et al. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 7, 3541\u20133550 (2023).","journal-title":"Blood Adv."},{"key":"3813_CR70","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue, J. M. et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica 106, 978\u2013986 (2021).","journal-title":"Haematologica"},{"key":"3813_CR71","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain, T., Olson, T. S. & Locke, F. L. How I treat cytopenias after CAR T-cell therapy. Blood 141, 2460\u20132469 (2023).","journal-title":"Blood"},{"key":"3813_CR72","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","volume":"8","author":"S Vic","year":"2024","unstructured":"Vic, S. et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study). Blood Adv. 8, 1573\u20131585 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2023000472","volume":"2023","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K., Subklewe, M. & Locke, F. L. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematol. Am. Soc. Hematol. Educ. Program 2023, 198\u2013208 (2023).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"3813_CR74","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","volume":"5","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud, A. et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 5, 4465\u20134475 (2021).","journal-title":"Blood Adv."},{"key":"3813_CR75","doi-asserted-by":"publisher","unstructured":"Rejeski K. et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood https:\/\/doi.org\/10.1182\/blood.2025028833 (2025).","DOI":"10.1182\/blood.2025028833"},{"key":"3813_CR76","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried, S. et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 54, 1643\u20131650 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR77","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am. J. Hematol. 98, 1699\u20131710 (2023).","journal-title":"Am. J. Hematol."},{"key":"3813_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05755-4","volume":"21","author":"K Rejeski","year":"2021","unstructured":"Rejeski, K. et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. BMC Infect. Dis. 21, 121 (2021).","journal-title":"BMC Infect. Dis."},{"key":"3813_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3919","volume":"9","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci. Adv. 9, eadg3919 (2023).","journal-title":"Sci. Adv."},{"key":"3813_CR80","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"3813_CR81","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL. Hemasphere 7, e858 (2023).","journal-title":"Hemasphere"},{"key":"3813_CR82","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1182\/blood.2024025910","volume":"145","author":"MS Nair","year":"2025","unstructured":"Nair, M. S. et al. Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood 145, 1136\u20131148 (2025).","journal-title":"Blood"},{"key":"3813_CR83","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz, R. A. et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J. Clin. Oncol. 36, 3043\u20133054 (2018).","journal-title":"J. Clin. Oncol."},{"key":"3813_CR84","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","volume":"8","author":"K Rejeski","year":"2024","unstructured":"Rejeski, K. et al. Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 8, 1857\u20131868 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR85","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Lievin","year":"2022","unstructured":"Lievin, R. et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 57, 431\u2013439 (2022).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00741-2","volume":"12","author":"KC Miller","year":"2022","unstructured":"Miller, K. C. et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 12, 146 (2022).","journal-title":"Blood Cancer J."},{"key":"3813_CR87","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","volume":"6","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K. et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 6, 4719\u20134725 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR88","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann, N. et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study. Blood Adv. 7, 555\u2013559 (2023).","journal-title":"Blood Adv."},{"key":"3813_CR89","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","volume":"59","author":"M Mohan","year":"2024","unstructured":"Mohan, M. et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 59, 647\u2013652 (2024).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR90","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","volume":"7","author":"G Drillet","year":"2023","unstructured":"Drillet, G., Lhomme, F., De Guibert, S., Manson, G. & Houot, R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. Blood Adv. 7, 537\u2013540 (2023).","journal-title":"Blood Adv."},{"key":"3813_CR91","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/ejh.14141","volume":"112","author":"W Wesson","year":"2024","unstructured":"Wesson, W. et al. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias. Eur. J. Haematol. 112, 538\u2013546 (2024).","journal-title":"Eur. J. Haematol."},{"key":"3813_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett, B. et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 14, 1303935 (2023).","journal-title":"Front. Immunol."},{"key":"3813_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101158","volume":"4","author":"P Strati","year":"2023","unstructured":"Strati, P. et al. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells. Cell Rep. Med. 4, 101158 (2023).","journal-title":"Cell Rep. Med."},{"key":"3813_CR94","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","volume":"15","author":"E Kampouri","year":"2022","unstructured":"Kampouri, E., Walti, C. S., Gauthier, J. & Hill, J. A. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev. Hematol. 15, 305\u2013320 (2022).","journal-title":"Expert Rev. Hematol."},{"key":"3813_CR95","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/cid\/ciz1127","volume":"71","author":"G Haidar","year":"2020","unstructured":"Haidar, G. et al. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clin. Infect. Dis. 71, 672\u2013676 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"3813_CR96","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora, S. B. et al. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect. Dis. 7, ofaa121 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"3813_CR97","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","volume":"5","author":"JH Baird","year":"2021","unstructured":"Baird, J. H. et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 5, 143\u2013155 (2021).","journal-title":"Blood Adv."},{"key":"3813_CR98","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","volume":"62","author":"T Wittmann Dayagi","year":"2021","unstructured":"Wittmann Dayagi, T. et al. Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leuk. Lymphoma 62, 1692\u20131701 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"3813_CR99","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","volume":"5","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 5, 5312\u20135322 (2021).","journal-title":"Blood Adv."},{"key":"3813_CR100","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","volume":"6","author":"JS Little","year":"2022","unstructured":"Little, J. S. et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv. 6, 4821\u20134830 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR101","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati, S. et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 6, 2045\u20132054 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR102","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan, M. et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 6, 2466\u20132470 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR103","doi-asserted-by":"publisher","first-page":"304 e1","DOI":"10.1016\/j.jtct.2022.03.005","volume":"28","author":"S Josyula","year":"2022","unstructured":"Josyula, S. et al. Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma. Transpl. Cell Ther. 28, 304 e1\u2013304.e9 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"3813_CR104","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 5, 5290\u20135299 (2021).","journal-title":"Blood Adv."},{"key":"3813_CR105","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue, J. M. et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 6, 6109\u20136119 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR106","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/cid\/ciad708","volume":"78","author":"E Kampouri","year":"2024","unstructured":"Kampouri, E. et al. Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin. Infect. Dis. 78, 1022\u20131032 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"3813_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae422","volume":"11","author":"F Khawaja","year":"2024","unstructured":"Khawaja, F. et al. Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes. Open Forum Infect. Dis. 11, ofae422 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"3813_CR108","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","volume":"8","author":"RY Lin","year":"2024","unstructured":"Lin, R. Y. et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 8, 3813\u20133822 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR109","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/blood.2024024145","volume":"144","author":"E Kampouri","year":"2024","unstructured":"Kampouri, E. et al. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients. Blood 144, 490\u2013495 (2024).","journal-title":"Blood"},{"key":"3813_CR110","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","volume":"106","author":"P Strati","year":"2021","unstructured":"Strati, P. et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106, 2667\u20132672 (2021).","journal-title":"Haematologica"},{"key":"3813_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28092","volume":"67","author":"DE Arnold","year":"2020","unstructured":"Arnold, D. E. et al. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients. Pediatr. Blood Cancer 67, e28092 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"3813_CR112","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41409-020-01027-6","volume":"56","author":"A Deya-Martinez","year":"2021","unstructured":"Deya-Martinez, A. et al. Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplant. 56, 376\u2013386 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR113","doi-asserted-by":"publisher","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","volume":"9","author":"JE Levine","year":"2021","unstructured":"Levine, J. E. et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J. Immunother. Cancer 9, e002287 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"3813_CR114","first-page":"e146743","volume":"6","author":"CS Walti","year":"2021","unstructured":"Walti, C. S. et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight 6, e146743 (2021).","journal-title":"JCI Insight"},{"key":"3813_CR115","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"3813_CR116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"VG Bhoj","year":"2016","unstructured":"Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128, 360\u2013370 (2016).","journal-title":"Blood"},{"key":"3813_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock, S. et al. Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. HemaSphere 9, e70062 (2025).","journal-title":"HemaSphere"},{"key":"3813_CR118","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/vaccines12091070","volume":"12","author":"G Angelidakis","year":"2024","unstructured":"Angelidakis, G. et al. Humoral immunity and antibody responses against diphtheria, tetanus, and pneumococcus after immune effector cell therapies: a prospective study. Vaccines 12, 1070 (2024).","journal-title":"Vaccines"},{"key":"3813_CR119","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14109","volume":"25","author":"G Reynolds","year":"2023","unstructured":"Reynolds, G., Hall, V. G. & Teh, B. W. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl. Infect. Dis. 25, e14109 (2023).","journal-title":"Transpl. Infect. Dis."},{"key":"3813_CR120","doi-asserted-by":"publisher","first-page":"e003428","DOI":"10.1136\/jitc-2021-003428","volume":"9","author":"CS Walti","year":"2021","unstructured":"Walti, C. S. et al. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. J. Immunother. Cancer 9, e003428 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"3813_CR121","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/cid\/ciae291","volume":"79","author":"JA Hill","year":"2024","unstructured":"Hill, J. A. et al. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T-cell therapy: a prospective, multicenter, observational study. Clin. Infect. Dis. 79, 542\u2013554 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"3813_CR122","doi-asserted-by":"crossref","first-page":"271.e1","DOI":"10.1016\/j.jtct.2023.01.020","volume":"29","author":"D Lee","year":"2023","unstructured":"Lee, D. et al. Pneumococcal conjugate vaccine does not induce humoral response when administrated within the six months after CD19 CAR T-cell therapy. Transplant. Cell Ther. 29, 271.e1\u2013277.e9 (2023).","journal-title":"Transplant. Cell Ther."},{"key":"3813_CR123","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","volume":"27","author":"J Meir","year":"2021","unstructured":"Meir, J., Abid, M. A. & Abid, M. B. State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses. Transpl. Cell Ther. 27, 973\u2013987 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"3813_CR124","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0140-6736(23)00872-3","volume":"402","author":"MB Abid","year":"2023","unstructured":"Abid, M. B. The denominator in early phase CAR T-cell trials examining novel target antigens. Lancet 402, 354\u2013356 (2023).","journal-title":"Lancet"},{"key":"3813_CR125","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","volume":"24","author":"BW Teh","year":"2024","unstructured":"Teh, B. W. et al. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Lancet Infect. Dis. 24, e59\u2013e68 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3813_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14154","volume":"26","author":"BW Teh","year":"2024","unstructured":"Teh, B. W., Mikulska, M., Mueller, N. J. & Slavin, M. A. Goals to score: the need for a minimum reporting dataset in studies of infection events in immunocompromised patients. Transpl. Infect. Dis. 26, e14154 (2024).","journal-title":"Transpl. Infect. Dis."},{"key":"3813_CR127","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1182\/bloodadvances.2024013859","volume":"8","author":"BW Teh","year":"2024","unstructured":"Teh, B. W., Reynolds, G. D., Mikulska, M., Mueller, N. J. & Slavin, M. A. Improving infection reporting in hematology treatment trials. Blood Adv. 8, 5925\u20135926 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR128","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain, T. et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol. Blood Marrow Transplant. 25, 2305\u20132321 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3813_CR129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald, G. B. et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann. Intern. Med. 172, 229\u2013239 (2020).","journal-title":"Ann. Intern. Med."},{"key":"3813_CR130","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","volume":"30","author":"Z Shahid","year":"2024","unstructured":"Shahid, Z. et al. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant. Cell Ther. 30, 955\u2013969 (2024).","journal-title":"Transplant. Cell Ther."},{"key":"3813_CR131","first-page":"540.e541","volume":"30","author":"Z Shahid","year":"2024","unstructured":"Shahid, Z. et al. Defining and grading infections in clinical trials involving hematopoietic cell transplantation: a report from the BMT CTN Infectious Disease Technical Committee. Transplant. Cell Ther. 30, 540.e541\u2013540.e513 (2024).","journal-title":"Transplant. Cell Ther."},{"key":"3813_CR132","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","volume":"11","author":"SA Patel","year":"2025","unstructured":"Patel, S. A., Spiegel, J. Y. & Dahiya, S. Second primary cancer after chimeric antigen receptor-T-cell therapy: a review. JAMA Oncol. 11, 174\u2013181 (2025).","journal-title":"JAMA Oncol."},{"key":"3813_CR133","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N. Engl. J. Med. 392, 677\u2013685 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR134","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577\u2013583 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR135","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3813_CR136","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery, R. et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat. Med. 31, 1130\u20131133 (2025).","journal-title":"Nat. Med."},{"key":"3813_CR137","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/cam4.5033","volume":"12","author":"F K\u00f3sa","year":"2023","unstructured":"K\u00f3sa, F. et al. Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe. Cancer Med. 12, 1961\u20131971 (2023).","journal-title":"Cancer Med."},{"key":"3813_CR138","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","volume":"10","author":"T Trab","year":"2023","unstructured":"Trab, T. et al. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 10, e838\u2013e848 (2023).","journal-title":"Lancet Haematol."},{"key":"3813_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107042","volume":"127","author":"M Miret","year":"2023","unstructured":"Miret, M. et al. Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients in England. Leuk. Res. 127, 107042 (2023).","journal-title":"Leuk. Res."},{"key":"3813_CR140","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/bloodadvances.2021006369","volume":"6","author":"J Joelsson","year":"2022","unstructured":"Joelsson, J. et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 6, 2657\u20132666 (2022).","journal-title":"Blood Adv."},{"key":"3813_CR141","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","volume":"8","author":"AJ Lamble","year":"2024","unstructured":"Lamble, A. J. et al. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 8, 3544\u20133548 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR142","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White, M. C. et al. Age and cancer risk: a potentially modifiable relationship. Am. J. Prev. Med. 46, S7\u2013S15 (2014).","journal-title":"Am. J. Prev. Med."},{"key":"3813_CR143","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/35041694","volume":"408","author":"RA DePinho","year":"2000","unstructured":"DePinho, R. A. The age of cancer. Nature 408, 248\u2013254 (2000).","journal-title":"Nature"},{"key":"3813_CR144","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","volume":"5","author":"LM Morton","year":"2019","unstructured":"Morton, L. M. et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 5, 318\u2013325 (2019).","journal-title":"JAMA Oncol."},{"key":"3813_CR145","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","volume":"17","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. J. Hematol. Oncol. 17, 19 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"3813_CR146","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","volume":"8","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 8, 653\u2013666 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR147","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi, G. et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann. Oncol. 33, 916\u2013928 (2022).","journal-title":"Ann. Oncol."},{"key":"3813_CR148","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"3813_CR149","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"3813_CR150","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"3813_CR151","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.ymthe.2023.07.015","volume":"31","author":"MD Tennant","year":"2023","unstructured":"Tennant, M. D., New, C., Ferreira, L. M. R. & O\u2019Neil, R. T. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling. Mol. Ther. 31, 2591\u20132599 (2023).","journal-title":"Mol. Ther."},{"key":"3813_CR152","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transpl. Cell Ther. 30, 1065\u20131079 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"3813_CR153","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","volume":"59","author":"OO Oluwole","year":"2024","unstructured":"Oluwole, O. O. et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 59, 366\u2013372 (2024).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR154","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","volume":"7","author":"P Strati","year":"2023","unstructured":"Strati, P. et al. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 7, 6785\u20136789 (2023).","journal-title":"Blood Adv."},{"key":"3813_CR155","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat. Med. 29, 1710\u20131717 (2023).","journal-title":"Nat. Med."},{"key":"3813_CR156","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","volume":"26","author":"E Huarte","year":"2020","unstructured":"Huarte, E. et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin. Cancer Res. 26, 6299\u20136309 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3813_CR157","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"3813_CR158","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2023-180205","volume":"142","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J. et al. Itacitinib for the prevention of immune effector cell therapy-associated cytokine release syndrome: results from the phase 2 INCB 39110-211 placebo-controlled randomized cohort. Blood 142, 356 (2023).","journal-title":"Blood"},{"key":"3813_CR159","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","volume":"181","author":"L Fugger","year":"2020","unstructured":"Fugger, L., Jensen, L. T. & Rossjohn, J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell 181, 63\u201380 (2020).","journal-title":"Cell"},{"key":"3813_CR160","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jha2.357","volume":"3","author":"MD Jain","year":"2022","unstructured":"Jain, M. D. & Spiegel, J. Y. Imagining the cell therapist: future CAR T cell monitoring and intervention strategies to improve patient outcomes. EJHaem 3, 46\u201353 (2022).","journal-title":"EJHaem"},{"key":"3813_CR161","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.omto.2021.03.003","volume":"20","author":"R Sakemura","year":"2021","unstructured":"Sakemura, R., Can, I., Siegler, E. L. & Kenderian, S. S. In vivo CART cell imaging: paving the way for success in CART cell therapy. Mol. Ther. Oncolytics 20, 625\u2013633 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"3813_CR162","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41409-024-02278-3","volume":"59","author":"EC Liang","year":"2024","unstructured":"Liang, E. C. et al. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Bone Marrow Transplant. 59, 910\u2013917 (2024).","journal-title":"Bone Marrow Transplant."},{"key":"3813_CR163","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"key":"3813_CR164","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3813_CR165","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"3813_CR166","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","volume":"12","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb, H. B. et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Cancer J. 12, 113 (2022).","journal-title":"Blood Cancer J."},{"key":"3813_CR167","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial car T cell therapy: analysis of FDA Adverse Events Reporting System (FAERS). Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"3813_CR168","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J. Am. Coll. Cardiol. 78, 1800\u20131813 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3813_CR169","first-page":"2452","volume":"141","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez, C., Neilan, T. G. & Grover, N. S. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood 141, 2452\u20132459 (2023).","journal-title":"Blood"},{"key":"3813_CR170","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","volume":"8","author":"M Munir","year":"2024","unstructured":"Munir, M., Sayed, A., Addison, D. & Epperla, N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 8, 6282\u20136296 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR171","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood.2024025679","volume":"144","author":"X Deschenes-Simard","year":"2024","unstructured":"Deschenes-Simard, X., Santomasso, B. D. & Dahi, P. B. Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood 144, 2083\u20132094 (2024).","journal-title":"Blood"},{"key":"3813_CR172","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","volume":"106","author":"R Nair","year":"2021","unstructured":"Nair, R. et al. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 106, 1504\u20131506 (2021).","journal-title":"Haematologica"},{"key":"3813_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.131","volume":"8","author":"A Couturier","year":"2024","unstructured":"Couturier, A. et al. Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel. Hemasphere 8, e131 (2024).","journal-title":"Hemasphere"},{"key":"3813_CR174","doi-asserted-by":"crossref","unstructured":"Bal, S. et al. S193: BMS-986393 (CC-95266), a G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 study. Hemasphere 7, e9863287 (2023).","DOI":"10.1097\/01.HS9.0000967684.98632.87"},{"key":"3813_CR175","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","volume":"22","author":"P Bindal","year":"2024","unstructured":"Bindal, P. et al. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J. Thromb. Haemost. 22, 2071\u20132080 (2024).","journal-title":"J. Thromb. Haemost."},{"key":"3813_CR176","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","volume":"11","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy. Cancer Immunol. Res. 11, 707\u2013719 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"3813_CR177","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/bloodadvances.2024014555","volume":"9","author":"YK Valtis","year":"2024","unstructured":"Valtis, Y. K. et al. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes. Blood Adv. 9, 151\u2013161 (2024).","journal-title":"Blood Adv."},{"key":"3813_CR178","doi-asserted-by":"publisher","first-page":"605.e601","DOI":"10.1016\/j.jtct.2022.06.002","volume":"28","author":"JA Ligon","year":"2022","unstructured":"Ligon, J. A. et al. Fertility and CAR T-cells: current practice and future directions. Transpl. Cell Ther. 28, 605.e601\u2013605.e608 (2022).","journal-title":"Transpl. Cell Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03813-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:40:32Z","timestamp":1757223632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03813-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":178,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03813-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.: Kite\/Gilead: research funding, consultancy, honoraria and travel support; Novartis: honoraria; BMS\/Celgene: consultancy, honoraria; Pierre-Fabre: travel support. J.A.H.: research funding: Allovir, Geovax, Takeda and Gilead; consultancy: Allovir, CSL Behring, Geovax, Karius, Gilead and Moderna. S.D.: research funding: Kite Pharma\/Gilead, Novartis and Kyverna Therapeutics; advisory board\/consulting: Kite Pharmaceuticals\/Gilead Pharma, Bristol Myers Squibb, Incyte, Adaptive Biotechnologies. M.D.J.: Kite\/Gilead: consultancy\/advisory, research funding; Novartis: consultancy\/advisory; Incyte: research funding; Lilly: research funding. None of these competing interests were related to the financing of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}